Log in

Relevant bibliographies by topics / Toxicodynamie

Contents

Journal articles

Academic literature on the topic 'Toxicodynamie'

Author: Grafiati

Published: 22 June 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Toxicodynamie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Toxicodynamie"

1

Kasteel, Emma E. J., Sandra M. Nijmeijer, Keyvin Darney, et al. "Acetylcholinesterase inhibition in electric eel and human donor blood: an in vitro approach to investigate interspecies differences and human variability in toxicodynamics." Archives of Toxicology 94, no. 12 (2020): 4055–65. http://dx.doi.org/10.1007/s00204-020-02927-8.

Full text

Abstract:

Abstract In chemical risk assessment, default uncertainty factors are used to account for interspecies and interindividual differences, and differences in toxicokinetics and toxicodynamics herein. However, these default factors come with little scientific support. Therefore, our aim was to develop an in vitro method, using acetylcholinesterase (AChE) inhibition as a proof of principle, to assess both interspecies and interindividual differences in toxicodynamics. Electric eel enzyme and human blood of 20 different donors (12 men/8 women) were exposed to eight different compounds (chlorpyrifos, chlorpyrifos-oxon, phosmet, phosmet-oxon, diazinon, diazinon-oxon, pirimicarb, rivastigmine) and inhibition of AChE was measured using the Ellman method. The organophosphate parent compounds, chlorpyrifos, phosmet and diazinon, did not show inhibition of AChE. All other compounds showed concentration-dependent inhibition of AChE, with IC50s in human blood ranging from 0.2–29 µM and IC20s ranging from 0.1–18 µM, indicating that AChE is inhibited at concentrations relevant to the in vivo human situation. The oxon analogues were more potent inhibitors of electric eel AChE compared to human AChE. The opposite was true for carbamates, pointing towards interspecies differences for AChE inhibition. Human interindividual variability was low and ranged from 5–25%, depending on the concentration. This study provides a reliable in vitro method for assessing human variability in AChE toxicodynamics. The data suggest that the default uncertainty factor of ~ 3.16 may overestimate human variability for this toxicity endpoint, implying that specific toxicodynamic-related adjustment factors can support quantitative in vitro to in vivo extrapolations that link kinetic and dynamic data to improve chemical risk assessment.

APA, Harvard, Vancouver, ISO, and other styles

2

Boak, Lauren M., Craig R. Rayner, M. Lindsay Grayson, et al. "Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid." Antimicrobial Agents and Chemotherapy 58, no. 4 (2014): 2334–43. http://dx.doi.org/10.1128/aac.01885-13.

Full text

Abstract:

ABSTRACTThrombocytopenia is a common side effect of linezolid, an oxazolidinone antibiotic often used to treat multidrug-resistant Gram-positive bacterial infections. Various risk factors have been suggested, including linezolid dose and duration of therapy, baseline platelet counts, and renal dysfunction; still, the mechanisms behind this potentially treatment-limiting toxicity are largely unknown. A clinical study was conducted to investigate the relationship between linezolid pharmacokinetics and toxicodynamics and inform strategies to prevent and manage linezolid-associated toxicity. Forty-one patients received 42 separate treatment courses of linezolid (600 mg every 12 h). A new mechanism-based, population pharmacokinetic/toxicodynamic model was developed to describe the time course of plasma linezolid concentrations and platelets. A linezolid concentration of 8.06 mg/liter (101% between-patient variability) inhibited the synthesis of platelet precursor cells by 50%. Simulations predicted treatment durations of 5 and 7 days to carry a substantially lower risk than 10- to 28-day therapy for platelet nadirs of <100 ×109/liter. The risk for toxicity did not differ noticeably between 14 and 28 days of therapy and was significantly higher for patients with lower baseline platelet counts. Due to the increased risk of toxicity after longer durations of linezolid therapy and large between-patient variability, close monitoring of patients for development of toxicity is important. Dose individualization based on plasma linezolid concentration profiles and platelet counts should be considered to minimize linezolid-associated thrombocytopenia. Overall, oxazolidinone therapy over 5 to 7 days even at relatively high doses was predicted to be as safe as 10-day therapy of 600 mg linezolid every 12 h.

APA, Harvard, Vancouver, ISO, and other styles

3

Blanchette, Alexander D., Sarah D. Burnett, Fabian A. Grimm, Ivan Rusyn, and Weihsueh A. Chiu. "A Bayesian Method for Population-wide Cardiotoxicity Hazard and Risk Characterization Using an In Vitro Human Model." Toxicological Sciences 178, no. 2 (2020): 391–403. http://dx.doi.org/10.1093/toxsci/kfaa151.

Full text

Abstract:

Abstract Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes are an established model for testing potential chemical hazards. Interindividual variability in toxicodynamic sensitivity has also been demonstrated in vitro; however, quantitative characterization of the population-wide variability has not been fully explored. We sought to develop a method to address this gap by combining a population-based iPSC-derived cardiomyocyte model with Bayesian concentration-response modeling. A total of 136 compounds, including 54 pharmaceuticals and 82 environmental chemicals, were tested in iPSC-derived cardiomyocytes from 43 nondiseased humans. Hierarchical Bayesian population concentration-response modeling was conducted for 5 phenotypes reflecting cardiomyocyte function or viability. Toxicodynamic variability was quantified through the derivation of chemical- and phenotype-specific variability factors. Toxicokinetic modeling was used for probabilistic in vitro-to-in vivo extrapolation to derive population-wide margins of safety for pharmaceuticals and margins of exposure for environmental chemicals. Pharmaceuticals were found to be active across all phenotypes. Over half of tested environmental chemicals showed activity in at least one phenotype, most commonly positive chronotropy. Toxicodynamic variability factor estimates for the functional phenotypes were greater than those for cell viability, usually exceeding the generally assumed default of approximately 3. Population variability-based margins of safety for pharmaceuticals were correctly predicted to be relatively narrow, including some below 10; however, margins of exposure for environmental chemicals, based on population exposure estimates, generally exceeded 1000, suggesting they pose little risk at current general population exposures even to sensitive subpopulations. Overall, this study demonstrates how a high-throughput, human population-based, in vitro-in silico model can be used to characterize toxicodynamic population variability in cardiotoxic risk.

APA, Harvard, Vancouver, ISO, and other styles

4

Kavlock, Robert J., and Gabriel L. Plaa. "Session summary: toxicodynamic interactive mechanisms." Toxicology 105, no. 2-3 (1995): 235–36. http://dx.doi.org/10.1016/0300-483x(95)03218-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ashauer, Roman, and Colin Brown. "TOXICODYNAMIC ASSUMPTIONS IN ECOTOXICOLOGICAL HAZARD MODELS." Environmental Toxicology and Chemistry preprint, no. 2008 (2007): 1. http://dx.doi.org/10.1897/07-642.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ashauer, Roman, and Colin D. Brown. "TOXICODYNAMIC ASSUMPTIONS IN ECOTOXICOLOGICAL HAZARD MODELS." Environmental Toxicology and Chemistry 27, no. 8 (2008): 1817. http://dx.doi.org/10.1897/07-642.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Serkova, Natalie J., and Uwe Christians. "Biomarkers for Toxicodynamic Monitoring of Immunosuppressants." Therapeutic Drug Monitoring 27, no. 6 (2005): 733–37. http://dx.doi.org/10.1097/01.ftd.0000179846.30342.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gots, Ronald E., and Suellen W. Pirages. "Multiple Chemical Sensitivities: Psychogenic or Toxicodynamic Origins." International Journal of Toxicology 18, no. 6 (1999): 393–400. http://dx.doi.org/10.1080/109158199225107.

Full text

Abstract:

The multiple chemical sensitivity (MCS) phenomenon can cause significant dysfunction and symptomatology and presents a difficult challenge for patient management. Central to the MCS debate is whether this phenomenon results from a primary emotional response to perceived chemical exposures or from pathological interactions between chemicals and biological systems. Those who believe the latter argue that toxic interactions result in physiological impairment and that subsequent emotional problems derive from such impairment. Distinguishing between psychogenic (emotional) or a toxicodynamic (chemical toxicity) origin is essential to the medical management of an MCS patient. A psychogenic basis requires treatment with appropriate behavioral therapies; in contrast, a belief in a strictly toxicodynamic etiology argues for avoidance and often precludes treatments that address the psychological responses. Current scientific evidence strongly suggests that behavioral or psychogenic explanations predominate for reported MCS symptoms. Acceptance of a purely toxic origination (i.e., pathological abnormalities result from a low level chemical exposure) defies known toxicological and medical principles; whereas psychogenic explanations are consistent with these principles. Because symptoms are the end points of many diseases with many causes, both physical and emotional, modern medicine is charged with and expected to consider both when treating MCS patients. The argument can be made that insufficient information exists about the causal nature of many diseases, and future research may provide support for a strict toxicodynamic cause. However, the practice of medicine must be based upon current knowledge, not future possibilities. Proper care of MCS patients requires identifying the existence of both psychological and organic pathological dysfunction. The rejection of a psychological aspect of the MCS phenomenon and appropriate behavioral treatments is both illogical and detrimental to MCS sufferers.

APA, Harvard, Vancouver, ISO, and other styles

9

Reeves, Andrew L. "Beryllium: Toxicological Research of the Last Decade." Journal of the American College of Toxicology 8, no. 7 (1989): 1307–13. http://dx.doi.org/10.3109/10915818909009122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Danilov-Danilyan, V. I., and O. M. Rozental. "Logistic Model of Population Toxicodynamics." Water Resources 49, no. 2 (2022): 231–39. http://dx.doi.org/10.1134/s0097807822020038.

Full text

Abstract:

Abstract The effect of pollutant in water on a population of aquatic organisms as a function of exposure time is studied. Natural assumptions are formulated regarding the character of this process, primarily, the linear relationship between the rate of decrease in the population, on the one hand, and the population size and the number of organisms killed by intoxication, on the other hand. The formulated assumptions are used to construct a model of population toxicodynamics, which describes the kinetics of suppression of the population by a logistic function. The results of model calculations are shown to agree with the available experimental data, thus justifying the formulated assumptions regarding the character of the intoxication process. An extension of the model is proposed through the incorporation of the dependence of the result of intoxication on pollutant concentration by the well-known Haber’s formula. The developed model was used to propose an equation of regulated toxicodynamics for organization of water use without violation of the regime of natural functioning of ecosystems. The obtained specification of the notions of the mechanisms of intoxication process is necessary for the substantiation of hygienic standards on the concentration of chemicals in water, forecasts of biodiversity, and the choice of measures for supporting weak components of trophic chains in aquatic ecosystems.

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!